Single Domain Antibody (SdAb) R&D in Hematological Disorders

Hematological disorders refer to diseases that primarily affect the blood & blood-forming organs. In general, hematological disorders include rare genetic disorders, anemia, lymphoma, leukemia, thrombocytopenia, etc.

Four Principal Components Affected by Hematological Disorders

Associated Diseases: Iron-deficiency anemia, anemia of chronic disease, pernicious anemia (B12 deficiency), aplastic anemia, autoimmune hemolytic anemia, thalassemia, sickle cell anemia, polycythemia vera, and malaria.

Associated Diseases: Lymphoma, leukemia, multiple myeloma, and myelodysplastic syndrome.

Associated Diseases: Thrombocytopenia, idiopathic thrombocytopenic purpura, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, and essential thrombocytosis (primary thrombocythemia).

Associated Diseases: Hemophilia, von Willebrand disease, hypercoagulable state, deep venous thrombosis, and disseminated intravascular coagulation (DIC).

Single domain antibody (sdAb) is a specialized antibody fragment derived from the heavy-chain-only antibodies found in camelids or sharks, or from specifically developed human VH and VL domains. Compared to conventional antibody formats, sdAbs offer significant advantages, including:

SdAbs can be efficiently produced in bacterial systems, and their modular nature allows for the creation of multivalent complexes. Recently, sdAbs have been investigated as potent therapeutics across various medical fields, including oncology, inflammatory diseases, neurological disorders, and hematological conditions.

Single Domain Antibody (SdAb) Discovered against Hematological Disorders

In recent years, several single domain antibodies (sdAbs) have been developed for hematological disorders. These sdAbs function by inhibiting platelet adhesion to vessel walls, thereby controlling platelet aggregation and clot formation. Measurements using the platelet aggregation biomarker (RICO) have demonstrated that sdAb injections are well tolerated and effectively inhibit von Willebrand factor (vWF)-mediated clotting. Additional research has focused on the treatment of thrombotic thrombocytopenic purpura (TTP), making sdAbs applicable to a broader patient population. In summary, sdAbs are versatile molecules with numerous advantageous properties for therapeutic and diagnostic applications, as well as for use as research tools.

Creative Biolabs is an expert in single domain antibody discovery and development, we have decade of experience and generate hundreds of de novel sdAbs to meet our global clients' requirements. Through all these demands, we have integrated and built requirements. Through all these demands, we have integrated and built up a series of one-stop solutions to offer better services to our further clients, these solutions including but not limited to:

If you are interested in discovering unique single domain antibodies to assist your projects, please do not hesitate to contact us for more details. Our scientists are pleased to offer highly customized services for you to earn success!

We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.

Online Inquiry
Interested in our expertise?

Contact us for more information

Get free consultations
USA
  • Tel:
  • Fax:
  • Email:
UK
  • Tel:
  • Email:
Germany
  • Tel:
  • Email:

Enter your email here to subscribe.

Submit

Follow us on

ISO 9001 Certified - Creative Biolabs Quality Management System.
Copyright © 2025 Creative Biolabs. All Rights Reserved.